Hydralazine as a Demethylating Agent in Rectal Cancer

Summary

Clinically feasible dose of Hydralazine for \~ 3 months, by virtue of its demethylating effect, will: 1. Result in re-expression of epigenetically silenced TSGs in rectal cancer specimens. 2. Decrease the global methylation in primary cancer cells compared to pre-treatment

Timeline

Start

2004-11

Primary completion

2008-05

Completion

—

Drugs

Indications